Core Insights - Harvard Bioscience, Inc. will showcase its latest product innovations at the Safety Pharmacology Society Annual Meeting from September 22-25, 2024, in San Diego [1] Product Innovations - The DSI™ Ponemah™ Data Management Platform integrates with DSI's SoHo™ implantable telemetry and VivaMARS™ behavior monitoring systems, providing a leading tool for managing and analyzing preclinical study data [2] - The SoHo™ telemetry system, introduced earlier this year, is now utilized by leading preclinical researchers for their testing needs [3] - The SoHo telemetry solution's small footprint allows for high-density studies in natural shared housing environments, reducing space needs and operating costs while increasing testing throughput [4] - The VivaMARS™ system offers a high-throughput platform for real-time behavioral testing in neuropharmacology safety and toxicology studies, supporting the needs of CROs and pharma companies [6] - The Mesh MEA™ organoid platform captures precise electrophysiology measurements from living organoids in real time, aimed at reducing the need for large population small model testing [8][9] Market Position and Future Outlook - Jim Green, Chairman and CEO of Harvard Bioscience, highlighted the commercial success of the wireless telemetry line and the collaboration with a leading customer to present data with the VivaMARS system [10] - The company is expanding its Mesh MEA Organoid Systems with installations at leading biotech, pharma, and CRO companies, as well as top academic institutions [10] - The company will exhibit its solutions at booth 501 during the Safety Pharmacology Society Annual Meeting [11]
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting